



Fax completed prior authorization request form to 855-247-3677 or submit Electronic Prior Authorization through CoverMyMeds® or SureScripts.

All requested data must be provided. **Incomplete forms or forms without the chart notes will be returned**

Pharmacy Coverage Guidelines are available at [www.mercycareaz.org/providers/rbha-forproviders/pharmacy](http://www.mercycareaz.org/providers/rbha-forproviders/pharmacy)

## Pulmonary Arterial Hypertension Agents Pharmacy Prior Authorization Request Form

Do not copy for future use. Forms are updated frequently

**REQUIRED: Office notes, labs and medical testing relevant to request showing medical justification are required to support diagnosis**

Member Information					
Member Name (first & last):		Date of Birth:		Gender:	
				<input type="checkbox"/> Male <input type="checkbox"/> Female	
Member ID:		City:		State:	
				Height:	
				Weight:	
Prescribing Provider Information					
Provider Name (first & last):		Specialty:		NPI#	
				DEA#	
Office Address:		City:		State:	
				Zip Code:	
Office Contact:			Office Phone		Office Fax:
Dispensing Pharmacy Information					
Pharmacy Name:		Pharmacy Phone:		Pharmacy Fax:	
Requested Medication Information					
Preferred Agents:	<input type="checkbox"/> Tracleer Tablets	<input type="checkbox"/> Letairis	<input type="checkbox"/> Adcirca	<input type="checkbox"/> Sildenafil	<input type="checkbox"/> Revatio suspension
Non-Preferred Agents:	<input type="checkbox"/> Revatio tab	<input type="checkbox"/> Upravi	<input type="checkbox"/> Orenitram ER	<input type="checkbox"/> Opsumit	<input type="checkbox"/> Adempas
	<input type="checkbox"/> epoprostenol	<input type="checkbox"/> Veletri	<input type="checkbox"/> Remodulin	<input type="checkbox"/> treprostinil	<input type="checkbox"/> Tyvaso
	<input type="checkbox"/> Ventavis	<input type="checkbox"/> Other, please specify:			
Are there any contraindications to formulary medications? If yes, please specify:				<input type="checkbox"/> Yes	<input type="checkbox"/> No
	<input type="checkbox"/> New request	<input type="checkbox"/> Continuation of therapy request			
For continuation of therapy requests ONLY:	<input type="checkbox"/> Response to therapy	<input type="checkbox"/> Maintained OR achieved low risk profile (for example, improvement in 6 min walk distance, functional class, or reducing time to clinical worsening)			
Directions for Use:		Strength:		Dosage Form:	
		Quantity:	Day Supply:	Duration of Therapy/Use:	
What medication(s) has member tried and failed for this diagnosis? Please specify:					
Medication request is NOT for an FDA approved, or compendia-supported diagnosis (circle one): Yes                      No			Diagnosis:		ICD-10 Code:
Turn-Around Time for Review					
<input type="checkbox"/> Standard – (24 hours)			<input type="checkbox"/> <b>Urgent</b> – If waiting 24 hours for a standard decision could seriously harm life, health, or ability to regain maximum function, you can ask for an expedited decision.		
Signature: _____					
Clinical Information - General Authorization Criteria					
Was there evidence of right heart catheterization with mPAP ≥25mmHg?	<input type="checkbox"/> Yes	<input type="checkbox"/> No	Is diagnosis of Pulmonary Arterial Hypertension WHO Group I with Functional Class II to IV symptoms?		<input type="checkbox"/> Yes <input type="checkbox"/> No
Did member have inadequate response OR intolerance to a CCB?	<input type="checkbox"/> Yes	<input type="checkbox"/> No	Was there a contraindication to use of CCBs?		<input type="checkbox"/> Yes <input type="checkbox"/> No
Did member have a negative vasoreactivity test?	<input type="checkbox"/> Yes	<input type="checkbox"/> No	Was there a contraindication to vasoreactivity test? (for example, low BP, low cardiac index, OR presence of severe Functional Class IV symptoms?)		<input type="checkbox"/> Yes <input type="checkbox"/> No
Did member have a positive vasoreactivity test with inadequate response OR intolerance to ONE CCB? (for example,	<input type="checkbox"/> Yes	<input type="checkbox"/> No	Will there be concurrent use of nitrate OR nitric oxide donors such as isosorbide mononitrate, isosorbide dinitrate OR		<input type="checkbox"/> Yes <input type="checkbox"/> No

amlodipine, nifedipine ER OR diltiazem)			nitroglycerin: Phosphodiesterase Type 5 Inhibitors AND Adempas?		
Is member pregnant?	<input type="checkbox"/> Yes	<input type="checkbox"/> No	Does member have hepatic impairment (Child Pugh class C)?	<input type="checkbox"/> Yes	<input type="checkbox"/> No
Does member have Pulmonary veno-occlusive disease?	<input type="checkbox"/> Yes	<input type="checkbox"/> No	Does member have HF with severe left ventricular dysfunction?	<input type="checkbox"/> Yes	<input type="checkbox"/> No
<b>Additional Drug Specific Criteria</b>					
<input type="checkbox"/> <b>Brand Revatio Oral Suspension</b>					
Does member an inability to swallow solid dosage form?				<input type="checkbox"/> Yes	<input type="checkbox"/> No
<input type="checkbox"/> <b>Adempas</b>					
Is diagnosis of WHO Pulmonary Arterial Hypertension Group I with NYHA Functional Class II to IV symptoms?				<input type="checkbox"/> Yes	<input type="checkbox"/> No
Member had trial AND failure with ONE preferred oral agent from each class (check that apply):		<b>(PDE-5) Inhibitor</b>		<b>Endothelin Receptor Antagonist</b>	
		<input type="checkbox"/> Sildenafil		<input type="checkbox"/> Tracleer tablets	
		<input type="checkbox"/> Tadalafil		<input type="checkbox"/> Letairis	
Is diagnosis for Chronic Thromboembolic Pulmonary Hypertension, WHO Group IV?	<input type="checkbox"/> Yes	<input type="checkbox"/> No	Was there recurrent OR persistent Chronic Thromboembolic Pulmonary Hypertension after surgical treatment?	<input type="checkbox"/> Yes	<input type="checkbox"/> No
Does member have inoperable Chronic Thromboembolic Pulmonary Hypertension?				<input type="checkbox"/> Yes	<input type="checkbox"/> No
<input type="checkbox"/> <b>Upravi - Orenitram</b>					
Does member have severe hepatic impairment (Child-Pugh class C)?				<input type="checkbox"/> Yes	<input type="checkbox"/> No
Trial AND failure with ONE preferred oral agent from each class (check that apply):		<b>(PDE-5) inhibitor</b>		<b>Endothelin Receptor Antagonist</b>	
		<input type="checkbox"/> Sildenafil		<input type="checkbox"/> Tracleer tablets	
		<input type="checkbox"/> Tadalafil		<input type="checkbox"/> Letairis	
<input type="checkbox"/> <b>Tyvaso - Ventavis - Remodulin - treprostinil</b>					
<u>Tyvaso and Ventavis ONLY:</u> Does member have NYHA Functional Class III-IV symptoms?	<input type="checkbox"/> Yes	<input type="checkbox"/> No	<u>Remodulin ONLY:</u> Does member have NYHA Functional Class II-IV symptoms?	<input type="checkbox"/> Yes	<input type="checkbox"/> No
Trial AND failure with ONE preferred oral agent from each class (check that apply):		<b>(PDE-5) inhibitor</b>		<b>Endothelin Receptor Antagonist</b>	
		<input type="checkbox"/> Sildenafil		<input type="checkbox"/> Tracleer tablets	
		<input type="checkbox"/> Tadalafil		<input type="checkbox"/> Letairis	
<b>Additional information the prescribing provider feels is important to this review. Please specify below or submit medical records</b>					

**Signature affirms that information given on this form is true and accurate and reflects office notes.**

**Prescribing Provider's Signature:** \_\_\_\_\_ **Date:** \_\_\_\_\_

**Please note: Incomplete forms or forms without the chart notes will be returned**  
Office notes, labs, and medical testing relevant to the request that show medical justification are required.  
Standard turnaround time is 24 hours. You can call 800-564-5465 to check the status of a request.